Skip to main content
MRNA
NASDAQ Life Sciences

Moderna Ebola Vaccine Cleared to Advance to Phase 2/3 Trial in Congo; Shares Up 8.2%

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$247.22
Mkt Cap
$98.699B
52W Low
$22.28
52W High
$254.48
52W Position info
1010% above low
Off High info
2.9% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

MRNA has more than doubled off its 52-week low of $22.28 on light trading volume (0.3× avg).

Summary

Moderna's mRNA-1469 Ebola vaccine was recommended to move into a Phase 2/3 trial in Congo, pending regulatory approval, targeting the Bundibugyo ebolavirus amid an ongoing outbreak there. The recommendation follows an October review by a WHO advisory group that weighed Phase 1 interim data showing the shot was generally well tolerated with encouraging signs of protective response. CEPI, which has committed up to $58.5 million for preclinical and Phase 1 work, is putting separate funding into the Phase 2/3 study. Shares rose 8.2% to $247.23 Wednesday, extending a year in which the stock has climbed more than eightfold on the back of the melanoma vaccine data. The trial is a modest commercial opportunity on its own — the real driver remains the intismeran cancer program — but it reinforces the mRNA platform narrative that has powered the stock to near its 52-week high.

At the time of this announcement, MRNA was trading at $247.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $98.7B. The 52-week trading range was $22.28 to $254.48. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

MRNA - Latest Insights

MRNA
Oct 24, 2026, 3:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $201.34
Real-time Price: $234.71 info
Change: +$33.37 (+17%) info
Market Cap: $96.399B info
MRNA
Oct 23, 2026, 8:35 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $183.84
Real-time Price: $234.71 info
Change: +$50.87 (+28%) info
Market Cap: $96.399B info
MRNA
Oct 22, 2026, 2:09 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $185.19
Real-time Price: $234.71 info
Change: +$49.52 (+27%) info
Market Cap: $96.399B info
MRNA
Oct 16, 2026, 12:09 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $212.67
Real-time Price: $234.71 info
Change: +$22.04 (+10%) info
Market Cap: $96.399B info
MRNA
Oct 12, 2026, 9:04 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $225.71
Real-time Price: $234.71 info
Change: +$9.00 (+4%) info
Market Cap: $96.399B info